Physician profile
Kara Schmidt
NPI 1205272101
$1,796.18
in general payments reported to CMS, 2019-2025
25 companies · $766 in 2025
The $766 reported for 2025 was more than what 79% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $15.74 · 2022: $153 · 2023: $362 · 2024: $499 · 2025: $766.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,611 · Education: $16.72.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,611.08 |
| Education | $16.72 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Supernus Pharmaceuticals, INC. | $388.28 | 2021-2025 | Qelbree, Qelbree |
| Jazz Pharmaceuticals INC. | $266.68 | 2022-2025 | |
| Otter Pharmaceuticals, LLC | $126.67 | 2024-2025 | Sympazan |
| Regeneron Healthcare Solutions, INC. | $114.87 | 2022-2025 | Dupixent |
| Ucb, INC. | $105.83 | 2024-2025 | Fintepla |
| Pfizer INC. | $82.77 | 2024-2025 | |
| Collegium Pharmaceutical, INC. | $82.52 | 2025 | Jornay Pm |
| Abbvie INC. | $80.73 | 2023-2025 | |
| Harmony Biosciences LLC | $73.22 | 2022-2025 | Wakix |
| Sk Life Science, INC. | $65.36 | 2025 | |
| Corium, LLC | $62.77 | 2023-2025 | Azstarys |
| Immedica Pharma US, INC. | $44.40 | 2023-2024 | |
| Idorsia Pharmaceuticals US INC | $43.89 | 2022-2023 | Quviviq |
| Ipsen Biopharmaceuticals, INC | $28.94 | 2023 | Dysport |
| Avadel Cns Pharmaceuticals, LLC | $28.87 | 2025 | Lumryz |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Livanova USA, INC. | $25.19 | 2025 | Vns Therapy Sentiva Model 1000 Generator |
| Teva Pharmaceuticals USA, INC. | $21.65 | 2025 | Austedo Xr |
| Neurelis, INC. | $21.38 | 2022 | |
| Biohaven Pharmaceutical Holding Company LTD. | $20.96 | 2022 | |
| Vertical Pharmaceuticals, LLC | $20.52 | 2025 | Relexxii |
| Ironshore Pharmaceuticals INC. | $20.50 | 2024 | |
| Sumitomo Pharma America, INC. | $19.74 | 2023 | Aptiom |
| Azurity Pharmaceuticals, INC. | $17.83 | 2025 | Alvesco |
| Catalyst Pharmaceuticals, INC. | $16.72 | 2024 | |
| Cranial Technologies, INC | $15.89 | 2024 | Doc Band |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kara Schmidt listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.